Medications for Managing Sleep in Critical Illness and Aftercare

Overview

Sleep disruption is common in critically ill patients due to physiological stress and ICU environmental factors. Pharmacologic interventions for sleep have shown limited efficacy and may increase risks such as delirium and falls, highlighting the importance of prioritizing non-pharmacologic sleep bundles before medication use.

Background

Sleep regulation involves circadian and homeostatic processes that are often disrupted during critical illness, compounded by stress hormones, inflammation, pain, anxiety, and ICU care interruptions. Poor sleep in the ICU is linked to adverse outcomes including delirium, which may have a bidirectional relationship with sleep quality. Pharmacologic sleep aids primarily target GABA receptors or melatonin pathways but have not consistently improved sleep quality or reduced delirium incidence. Non-pharmacologic interventions remain the first-line approach to improve sleep in critically ill patients.

Data Highlights

Critically ill patients are typically prescribed 8–12 medications, contributing to polypharmacy and increased risk of poor outcomes. Systematic reviews indicate that sleep bundles incorporating non-pharmacologic and pharmacologic measures can reduce delirium incidence, though pharmacologic agents alone have disappointing results. GABA agonists like propofol and benzodiazepines, despite their sedative effects, do not reliably improve sleep quality in the ICU setting.

Key Findings

• Sleep in critical illness is disrupted by physiological stress, inflammation, and ICU environmental factors.
• Non-pharmacologic sleep bundles are the current gold standard for improving sleep in ICU patients.
• Pharmacologic hypnotics, including GABA agonists, have limited efficacy in improving sleep and may increase risks such as delirium and falls.
• Melatonin supplementation and melatonin receptor agonists are explored to enhance circadian regulation but require further evidence.
• Sleep disruption and delirium may have a bidirectional relationship involving altered CNS connectivity and melatonin dysregulation.
• Promoting wakefulness during the day to consolidate nocturnal sleep is a potential therapeutic strategy under investigation.

Clinical Implications

Clinicians should prioritize non-pharmacologic interventions to improve sleep in critically ill patients before considering medications. When pharmacotherapy is necessary, awareness of potential adverse effects such as delirium and falls is critical. Strategies that address both circadian and homeostatic sleep regulation, including melatonin-based therapies and wakefulness promotion, may offer future benefits but require further validation.

Conclusion

Pharmacologic management of sleep in critical illness remains challenging with limited proven benefits and potential harms. A bundled approach emphasizing non-pharmacologic measures alongside cautious, targeted pharmacotherapy offers the best current strategy to improve sleep and potentially reduce delirium in ICU patients.

References

1. Critical Care Sleep and Delirium Research Group 2023 -- Medications for Managing Sleep in Critical Illness and Aftercare